The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database

The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database

The first-generation tropomyosin receptor kinase (TRK) inhibitors, larotrectinib and entrectinib, represent exciting new developments in cancer treatment that offer relevant, rapid, and long-lasting clinical benefits. Larotrectinib and entrectinib are recommended as first-line treatments for locally...

Full description

Bibliographic Details
Main Authors: Valerio Liguori, Mario Gaio, Alessia Zinzi, Cecilia Cagnotta, Consiglia Riccardi, Giovanni Docimo, Annalisa Capuano
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Biomedicines
Subjects:
TRK
NTRK
agnostic drugs
precision medicine
larotrectinib
entrectinib
Online Access:https://www.mdpi.com/2227-9059/11/9/2538

Internet

https://www.mdpi.com/2227-9059/11/9/2538

Similar Items